Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Most Closely HLA-Matched Allogeneic LMP1/2-Specific Cytotoxic T Lymphocytes for Treatment of Patients With Relapsed EBV-Associated Diseases

NCT01447056 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT01447056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01447056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Most Closely HLA-Matched Allogeneic LMP1/2-Specific Cytotoxic T Lymphocytes for Treatment of Patients With Relapsed EBV-Associated Diseases
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Completed
Start date
February 29, 2012
Completion date
January 22, 2020
Enrollment
37 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma, leiomyosarcoma, lymphoproliferative disorder, nasopharyngeal carcinoma, non-hodgkin lymphoma, severe chronic active ebv (scaebv)